CO6541577A2 - Nuevas formas polimorfas de {4.6- diamino -2-[1-(2-fluorobencil)-1h- pirazolo[3.4-b]piridin-3il] pirimidin -5il} carbamato de metilo - Google Patents
Nuevas formas polimorfas de {4.6- diamino -2-[1-(2-fluorobencil)-1h- pirazolo[3.4-b]piridin-3il] pirimidin -5il} carbamato de metiloInfo
- Publication number
- CO6541577A2 CO6541577A2 CO12085982A CO12085982A CO6541577A2 CO 6541577 A2 CO6541577 A2 CO 6541577A2 CO 12085982 A CO12085982 A CO 12085982A CO 12085982 A CO12085982 A CO 12085982A CO 6541577 A2 CO6541577 A2 CO 6541577A2
- Authority
- CO
- Colombia
- Prior art keywords
- diamino
- new forms
- mettilo
- fluorobencil
- polymorphes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a nuevas formas de {4,6-diamino-2-[1-(2- fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-iI}carbamato de metilo de fórmula (1), de forma particular la modificación 1, a procedimientos para su preparación, a medicamentos que lo contienen así como a su uso para el tratamiento de enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09177373 | 2009-11-27 | ||
EP09177908 | 2009-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6541577A2 true CO6541577A2 (es) | 2012-10-16 |
Family
ID=43530231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12085982A CO6541577A2 (es) | 2009-11-27 | 2012-05-24 | Nuevas formas polimorfas de {4.6- diamino -2-[1-(2-fluorobencil)-1h- pirazolo[3.4-b]piridin-3il] pirimidin -5il} carbamato de metilo |
Country Status (21)
Country | Link |
---|---|
US (1) | US20110183999A1 (es) |
EP (1) | EP2504337A1 (es) |
JP (1) | JP2013512213A (es) |
KR (1) | KR20120098816A (es) |
CN (1) | CN102741246A (es) |
AR (1) | AR079136A1 (es) |
AU (1) | AU2010323245A1 (es) |
BR (1) | BR112012012458A2 (es) |
CA (1) | CA2781808A1 (es) |
CO (1) | CO6541577A2 (es) |
CU (1) | CU20120081A7 (es) |
DO (1) | DOP2012000142A (es) |
EA (1) | EA201270629A1 (es) |
EC (1) | ECSP12011923A (es) |
IL (1) | IL219826A0 (es) |
MA (1) | MA33765B1 (es) |
MX (1) | MX2012005944A (es) |
TN (1) | TN2012000258A1 (es) |
TW (1) | TW201139433A (es) |
UY (1) | UY33040A (es) |
WO (1) | WO2011064189A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY180184A (en) | 2009-11-27 | 2020-11-24 | Adverio Pharma Gmbh | Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
DK2896617T3 (en) | 2011-11-25 | 2016-12-12 | Adverio Pharma Gmbh | Method for preparing substituted (Z) -alpha-fluoro-beta-amino-ACRYLALDEHYDER |
JP6386478B2 (ja) | 2013-02-21 | 2018-09-05 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | メチル{4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1h−ピラゾロ[3,4−b]ピリジノ−3−イル]ピリミジノ−5−イル}メチルカルバメートの形態 |
CN104327107A (zh) * | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
CN111246849A (zh) * | 2017-10-19 | 2020-06-05 | 株式会社佐藤园 | 学习记忆能力增强组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
US6452805B1 (en) * | 1999-09-29 | 2002-09-17 | Silicon Graphics, Inc. | Computer module mounting system and method |
DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
US7137037B2 (en) * | 2003-03-27 | 2006-11-14 | Silicon Motion, Inc. | Data storage system and method for testing the same |
DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
-
2010
- 2010-11-19 UY UY0001033040A patent/UY33040A/es not_active Application Discontinuation
- 2010-11-23 BR BR112012012458A patent/BR112012012458A2/pt not_active IP Right Cessation
- 2010-11-23 KR KR1020127016595A patent/KR20120098816A/ko not_active Application Discontinuation
- 2010-11-23 EP EP10784755A patent/EP2504337A1/de not_active Withdrawn
- 2010-11-23 MX MX2012005944A patent/MX2012005944A/es not_active Application Discontinuation
- 2010-11-23 CA CA2781808A patent/CA2781808A1/en not_active Abandoned
- 2010-11-23 WO PCT/EP2010/067985 patent/WO2011064189A1/de active Application Filing
- 2010-11-23 CN CN2010800537098A patent/CN102741246A/zh active Pending
- 2010-11-23 AU AU2010323245A patent/AU2010323245A1/en not_active Abandoned
- 2010-11-23 EA EA201270629A patent/EA201270629A1/ru unknown
- 2010-11-23 JP JP2012540395A patent/JP2013512213A/ja active Pending
- 2010-11-24 AR ARP100104328A patent/AR079136A1/es unknown
- 2010-11-26 TW TW099140894A patent/TW201139433A/zh unknown
- 2010-11-29 US US12/954,961 patent/US20110183999A1/en not_active Abandoned
-
2012
- 2012-05-16 IL IL219826A patent/IL219826A0/en unknown
- 2012-05-24 TN TNP2012000258A patent/TN2012000258A1/en unknown
- 2012-05-24 CO CO12085982A patent/CO6541577A2/es not_active Application Discontinuation
- 2012-05-24 DO DO2012000142A patent/DOP2012000142A/es unknown
- 2012-05-24 EC ECSP12011923 patent/ECSP12011923A/es unknown
- 2012-05-24 CU CU2012000081A patent/CU20120081A7/es unknown
- 2012-05-25 MA MA34894A patent/MA33765B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
MA33765B1 (fr) | 2012-11-01 |
IL219826A0 (en) | 2012-07-31 |
CA2781808A1 (en) | 2011-06-03 |
JP2013512213A (ja) | 2013-04-11 |
TN2012000258A1 (en) | 2013-12-12 |
MX2012005944A (es) | 2012-10-03 |
BR112012012458A2 (pt) | 2017-10-10 |
WO2011064189A1 (de) | 2011-06-03 |
AU2010323245A1 (en) | 2012-06-14 |
CU20120081A7 (es) | 2012-10-15 |
TW201139433A (en) | 2011-11-16 |
US20110183999A1 (en) | 2011-07-28 |
ECSP12011923A (es) | 2012-07-31 |
UY33040A (es) | 2011-06-30 |
KR20120098816A (ko) | 2012-09-05 |
EA201270629A1 (ru) | 2013-01-30 |
EP2504337A1 (de) | 2012-10-03 |
DOP2012000142A (es) | 2013-01-15 |
AR079136A1 (es) | 2011-12-28 |
CN102741246A (zh) | 2012-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6541577A2 (es) | Nuevas formas polimorfas de {4.6- diamino -2-[1-(2-fluorobencil)-1h- pirazolo[3.4-b]piridin-3il] pirimidin -5il} carbamato de metilo | |
DOP2020000062A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico | |
GT201300137A (es) | Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak | |
CR20110270A (es) | Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades | |
BRPI0919292A2 (pt) | 3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios | |
CL2009000447A1 (es) | Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf. | |
CL2011000917A1 (es) | Compuestos derivados de tioamida; sus metodos de preparacion y uso de los compuestos para el tratamiento de enfermedades endoparasitarias. | |
MX349004B (es) | Nuevos compuestos. | |
UY33503A (es) | Imidazo [1,2-a]pirimidinas y piridinas sustituidas | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
BR112013023876A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
CL2012000248A1 (es) | Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina. | |
ECSP10010582A (es) | Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer | |
DK3489238T3 (da) | Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser | |
MX2011009847A (es) | Agentes antihelminticos y su uso. | |
ECSP099751A (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazo[4,5-b]piridin-5-amina y su uso para el tratamiento del cáncer | |
CO6551707A2 (es) | Procedimiento para la preparaciçon de {4.6-diamino-2[1-2(2-fluorobencil)-1h- pirazolo [3.4-b]piridin -3-il] pirimidin -5-il} carbamato de metilo y su purificación para el uso como principio activo farmacéutico | |
CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
CO6382113A2 (es) | Compuestos quimicos | |
WO2014029888A3 (en) | Branched or macrocyclic polyamines and uses thereof | |
MX2008013477A (es) | Compuestos biciclicos de tetrahidropirrol. | |
EA201390620A1 (ru) | ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ | |
EA201390619A1 (ru) | 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения | |
TN2013000231A1 (en) | Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |